Equities

Healius Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Healius Ltd

Actions
  • Price (EUR)0.47
  • Today's Change0.012 / 2.62%
  • Shares traded189.00
  • 1 Year change-45.98%
  • Beta0.7477
Data delayed at least 15 minutes, as of Feb 17 2026 07:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Healius Limited is a healthcare company. The Company’s specialized pathology businesses deliver healthcare services across Australia. It provides pathology services, including specialty pathology and clinical trials. It offers its medical laboratory and pathology services through a variety of specialty brands. It provides medical laboratory and pathology services across key diagnostic activities. These include anatomical pathology (histopathology and cytology), clinical pathology (biochemistry, hematology, immunology and microbiology), genomic diagnostics and veterinary pathology. Its brands include QML, Laverty, Dorevitch, Western Diagnostic Pathology, TML, Agilex Biolabs, and Abbott Pathology, among others. These brands operate in Queensland, New South Wales (including the Australian Capital Territory), Victoria, Western Australia and Northern Territory, Tasmania, and South Australia. It provides specialty diagnostic services to consumers and their referring practitioners.

  • Revenue in AUD (TTM)1.34bn
  • Net income in AUD-563.00m
  • Incorporated1994
  • Employees8.00k
  • Location
    Healius LtdLevel 22Liberty Place, 161 Castlereagh StreetSYDNEY 2000AustraliaAUS
  • Phone+61 29432-9400
  • Fax+61 29432-9447
  • Websitehttps://www.healius.com.au/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.